Topics
natalizumabChemical substance
Selection of a follow-on treatment option in patients who discontinue natalizumab is a common clinical issue, especially in patients at risk of developing pro-gressive multifocal leukoencephalopathy (PML
Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis w...
Joachim Havla,1 Ingo Kleiter,2 Tania Kümpfel11Institute of Clinical Neuroimmunology, Medical Ca...
Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relap...
Treatment with natalizumab is a double-edged sword: profound efficacy meets the medical need especia...
Natalizumab has a great impact on disease activity in patients with multiple sclerosis (MS)1; howeve...
Progressive multifocal leukoencephalopathy (PML) is one of the major risks of natalizumab therapy. D...
The infusion of 300 mg of natalizumab every 4 weeks is an effective therapy for reducing disease act...
Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multip...
Natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). Howev...
The objective of this paper is to estimate the risk of reaching well-established disability mileston...
Natalizumab is approved for the treatment of patients with relapsing–remitting multiple sclerosis wh...
In the context of an increasing repertoire of multiple sclerosis (MS) therapeutics, choosing the app...
Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis w...
Joachim Havla,1 Ingo Kleiter,2 Tania Kümpfel11Institute of Clinical Neuroimmunology, Medical Ca...
Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relap...
Treatment with natalizumab is a double-edged sword: profound efficacy meets the medical need especia...
Natalizumab has a great impact on disease activity in patients with multiple sclerosis (MS)1; howeve...
Progressive multifocal leukoencephalopathy (PML) is one of the major risks of natalizumab therapy. D...
The infusion of 300 mg of natalizumab every 4 weeks is an effective therapy for reducing disease act...
Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multip...
Natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). Howev...
The objective of this paper is to estimate the risk of reaching well-established disability mileston...
Natalizumab is approved for the treatment of patients with relapsing–remitting multiple sclerosis wh...
In the context of an increasing repertoire of multiple sclerosis (MS) therapeutics, choosing the app...
Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis w...
Joachim Havla,1 Ingo Kleiter,2 Tania Kümpfel11Institute of Clinical Neuroimmunology, Medical Ca...
Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relap...
Add to ORKG